Q32 Bio Inc.
Q32 Bio Inc. is a U.S.-based clinical-stage biotechnology company focused on developing biologic medicines for autoimmune and inflammatory diseases. Its lead program, bempikibart (ADX-914), is an anti-IL-7Rα monoclonal antibody being studied for alopecia areata and other immune-mediated conditions.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaBempikibart (ADX-914), a fully human anti-IL-7Rα monoclonal antibody in clinical development.
Early- and mid-stage development programs targeting autoimmune and inflammatory diseases.
Asiakkaat
Q32 Bio does not sell commercial products today; its current counterparties are clinical trial participants, investigators, research sites, and third-party manufacturers that support development. If approved in the future, its medicines would be used by patients with autoimmune and inflammatory diseases and prescribed by physicians, with reimbursement decisions made by payors.
Patients enrolled in SIGNAL-AA and other studies who receive investigational bempikibart.
Hospitals, clinics, and investigators that recruit, dose, and monitor patients in studies.
Contract manufacturers that supply biologic drug substance and drug product for development.
Physicians and reimbursement bodies that would determine adoption after approval.
Strategia
Q32 Bio's strategy is centered on advancing bempikibart through clinical development in alopecia areata and evaluating its broader potential in autoimmune and inflammatory disease. The company also relies on external manufacturing and may pursue in-licensing or acquisitions that complement its pipeline.
Clinical data are the main value driver for a single-asset biotech.
Broader autoimmune use could increase the commercial value of the platform.
Biologics require reliable external supply and process control.
Maantiede
Q32 Bio is headquartered in Waltham, Massachusetts and incorporated in Delaware, with its principal operations centered in the United States. The company intends to seek approval in the U.S. and selected foreign jurisdictions, so future development and commercialization could extend beyond its current domestic base.
Riskit
Q32 Bio faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, dependence on external capital, and the possibility that its product candidates never reach approval or commercialization. Its business also depends on third-party manufacturing, regulatory clearance, and future reimbursement access if any product is approved.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Bempikibart is still in clinical testing, so efficacy or safety results may not support approval.
Kohdistuu: Lead program in alopecia areata and other autoimmune diseases
- Need for external financingVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company does not expect current cash to fund development through approval.
Kohdistuu: Pipeline advancement and potential commercialization
- Manufacturing dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Biologic supply relies on third-party vendors and specialized production capability.
Kohdistuu: Clinical supply and future commercial scale-up
- Regulatory and reimbursement uncertaintyVaikutus: KorkeaTodennäköisyys: Kohtalainen
Approval, labeling, and payer coverage will determine whether any future product can be commercialized.
Kohdistuu: U.S. and selected foreign markets
Kirjanpito
Harkinnanvaraiset erätClinical trial and manufacturing costs are expensed as incurred and drive most period-to-period variation.
Vaikutus: Affects operating loss and comparability across quarters
The company recognized non-cash revenue from the Amgen Amendment, which is not expected to recur.
Vaikutus: Can create large one-time revenue and earnings swings
Non-operating items such as convertible note valuation can affect reported results when present.
Vaikutus: Can distort underlying operating performance
Equity awards are a meaningful part of compensation in development-stage biotech companies.
Vaikutus: Raises reported operating expense without cash outflow
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
ImageneBio, Inc.
IMA · Biological Products, (No Diagnostic Substances)
GRI Bio, Inc.
GRI · Pharmaceutical Preparations
Evommune, Inc.
EVMN · Pharmaceutical Preparations
Dianthus Therapeutics, Inc.
DNTH · Pharmaceutical Preparations
Dianthus Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for autoimmune and inflammatory diseases.
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
Ventyx Biosciences, Inc.
Pharmaceutical Preparations
Päivitetty: 24.9.2026